Stocktoria
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2009-05-01
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6,000 | $11,000 | $9,000 | $88,600 | $87,754 | $164,500 | $165,500 | $124,400 | $4,800 | $0 |
| Gross profit | $3,806 | $6,600 | $5,400 | $60,109 | $39,805 | $113,904 | $120,001 | $54,025 | -$3,200 | $0 |
| R&D expense | $2.3M | $2.4M | $2.0M | $6.3M | $109,180 | $0 | $0 | $96,621 | $260,085 | $85,334 |
| SG&A expense | $3.8M | $3.2M | $3.6M | $3.9M | $3.0M | $1.2M | $1.2M | $1.1M | — | — |
| Operating income | -$6.1M | -$5.7M | -$5.6M | -$10.2M | -$3.1M | -$1.1M | -$1.1M | -$1.1M | -$1.2M | -$759,674 |
| Interest expense | — | — | — | $0 | $4.3M | $1.2M | $1.9M | $1.4M | $377,587 | $6,398 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M | -$36.3M | -$8.5M | -$13.7M | -$2.7M | -$766,072 |
| EPS (diluted) | $-2.52 | $-3.71 | $-3.76 | $-0.93 | $5.61 | $-62.69 | — | — | — | — |
| Operating cash flow | -$5.9M | -$5.3M | -$8.0M | -$7.8M | -$2.2M | -$434,556 | -$1.2M | -$1.1M | -$889,621 | -$445,232 |
| Cash & equivalents | — | — | — | $8.3M | $10.7M | $98,012 | $88,648 | $304,056 | $13,697 | $221,868 |
| Inventory | $0 | $2,194 | $6,594 | $10,194 | $10,866 | $0 | $0 | — | — | — |
| Total assets | $7.8M | $6.7M | $10.7M | $19.2M | $11.3M | $717,775 | $530,803 | $477,161 | $203,147 | $322,512 |
| Total liabilities | $284,880 | $327,644 | $371,394 | $3.3M | $1.1M | $40.5M | $8.6M | $4.5M | $2.4M | $480,303 |
| Shareholders' equity | $7.5M | $6.3M | $10.3M | $15.9M | $10.2M | -$39.8M | -$8.1M | -$4.0M | -$2.2M | -$157,791 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -45.5% | +22.2% | -89.8% | +1.0% | -46.7% | -0.6% | +33.0% | +2491.7% | — | — |
| Net income growth | — | — | — | -152.8% | — | — | — | — | — | — |
| EPS growth | — | — | — | -116.6% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.